RecruitingNCT05022914

PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE

Prostate-Specific Membrane Antigen (PSMA) Guided Approach for bIoCHEmical Relapse After Prostatectomy- A Prospective Observational Study-PSICHE


Sponsor

Azienda Ospedaliero-Universitaria Careggi

Enrollment

180 participants

Start Date

Jan 19, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

This observational study was designed to evaluate progression free survival after PSMA-PET/CT based salvage approach for patients affected by biochemical relapse after radical prostatectomy.


Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether using a specialized PET scan (68Ga-PSMA PET/CT) to precisely locate where prostate cancer has returned after surgery can help guide more targeted salvage treatment, potentially improving outcomes. **You may be eligible if...** - You previously had your prostate removed (radical prostatectomy) for prostate cancer - Your PSA (a blood marker for prostate cancer) is between 0.2 and 1.0 ng/ml — indicating a biochemical relapse (cancer coming back) - You may or may not have had post-surgery radiation already - Your doctor has recommended a PSMA PET/CT scan as part of standard re-staging **You may NOT be eligible if...** - You received androgen deprivation therapy (hormone therapy) within the last 6 months - Your PSA remained elevated immediately after surgery (above 0.1 ng/ml within 16 weeks of surgery), indicating incomplete removal Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

AOU Careggi Radiation Oncology Unit

Florence, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05022914


Related Trials